ImmunoBrain Checkpoint
Disease-modifying Immunotherapies for Neurodegenerative Disorders
Company Overview
Snapshot
Founded in February 2015 by Prof. Michal Shwartz, ImmunoBrain Checkpoint operates with 11–50 employees. The company is focused on developing disease-modifying immunotherapies for neurological disorders. In October 2017, ImmunoBrain Checkpoint secured seed funding from SBI JI Innovation Fund to advance its research.
Business overview
ImmunoBrain Checkpoint (IBC) is a biopharmaceutical company developing a pipeline of disease-modifying immunotherapies for neurological disorders. The company's core technology targets immune checkpoint pathways, with lead programs focused on treating Alzheimer's disease by blocking the PD-1/PD-L1 immune checkpoint pathway. IBC serves the pharmaceutical and biotechnology sectors, aiming to address neurodegenerative conditions.
Strategic signal
ImmunoBrain Checkpoint is actively strengthening its leadership and scientific expertise, as evidenced by the appointments of Dr. Francis S. Collins in October 2025 and Rochelle Walensky, MD, MPH, in September 2025 to its Board of Directors. These additions signal a strategic move to bring high-profile medical and scientific leadership to guide the company's clinical development and strategic direction, particularly as it prepares to present Phase 1b clinical data for its Alzheimer's treatment in March 2026.
Log in to access full profile ›Company Intelligence Q&A
- When was ImmunoBrain Checkpoint founded?
- ImmunoBrain Checkpoint was founded in February 2015.
- What is ImmunoBrain Checkpoint's primary focus?
- ImmunoBrain Checkpoint is focused on developing disease-modifying immunotherapies for neurological disorders by targeting immune checkpoint pathways.
- What significant clinical data did ImmunoBrain Checkpoint announce in March 2026?
- In March 2026, ImmunoBrain Checkpoint announced plans to present topline Phase 1b clinical data for its immune checkpoint treatment in Alzheimer's disease at ADPD 2026.
- Which global pharmaceutical company obtained rights to ImmunoBrain Checkpoint's research in June 2017?
- In June 2017, Lundbeck, a global pharmaceutical company specializing in therapies for neurological disorders, obtained the rights to ImmunoBrain Checkpoint's research into treatment for Alzheimer's disease.
- Who joined ImmunoBrain Checkpoint's Board of Directors in October 2025?
- In October 2025, Dr. Francis S. Collins joined ImmunoBrain Checkpoint's Board of Directors.